Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Nyan Heroes, a blockchain game, announces cessation of operations, previously garnered over 250,000 player reservations

Nyan Heroes, a blockchain game, announces cessation of operations, previously garnered over 250,000 player reservations

BlockBeatsBlockBeats2025/05/17 13:20
Show original

According to the official announcement, due to the latest product failing to reach the expected user scale, combined with the current Web3 market environment facing numerous challenges, the blockchain game Nyan Heroes was unable to secure the funding needed to maintain studio operations and ultimately decided to cease operations.

 

It is reported that Nyan Heroes received over 250,000 player reservations on the Epic and Steam platforms, with four test events attracting over 1 million participants in total. The game frequently appeared on Epic Games' popular and most-played lists and was covered by traditional media such as IGN, Business Insider, and Game Rant. Despite the project team exploring various options such as issuance, new investments, grants, and acquisitions, they ultimately failed to raise the funds necessary to complete the game's development.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

智通财经•2026/10/26 06:41
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential

Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.

智通财经•2026/10/26 06:37